Actuate Therapeutics, Inc. (ACTU) Stock Forecast
ACTU analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 3 analysts
- Price target
- $11.68 average of analyst targets
- Upside to target
- +1,831.1% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.18
- 52-week range
- $0.43 – $7.63
ACTU analyst ratings
3 analystsNumber of analysts at each rating.
ACTU price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ACTU earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.17 | −$0.21 | −$0.15 | −$0.25 | +32.0% | 3 |
| Current fiscal year (2026) | −$0.73 | −$0.85 | −$0.61 | −$1.06 | +31.4% | 3 |
| Next fiscal year (2027) | −$0.66 | −$0.82 | −$0.51 | −$0.73 | +8.7% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ACTU revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 3 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 3 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 3 |
ACTU EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ACTU EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.19 | −$0.19 | −$0.15 | −$0.17 | −10.5% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.78 | −$0.78 | −$0.78 | −$0.67 | −$0.73 | −6.4% | 1 up · 1 down |
| Next fiscal year (2027) | −$0.85 | −$0.85 | −$0.85 | −$0.72 | −$0.66 | −22.0% | 3 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ACTU earnings surprises
Reported EPS vs the consensus estimate for the last 9 quarters; ACTU beat in 4 of 7.
What analysts expect from ACTU
3 analysts cover Actuate Therapeutics; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $11.68, 1,831.1% above the latest close of $0.60. Analysts expect earnings of −$0.73 per share for 2026, +31.4% from a year earlier. For 2027 the average estimate is −$0.66 per share. Actuate Therapeutics beat the EPS estimate in 4 of the last 7 quarters.
Related: ACTU income statement, ACTU key metrics, ACTU chart. See the ACTU stock overview for the latest quote and news.
ACTU forecast FAQ
What is Actuate Therapeutics's price target?
The average analyst price target for Actuate Therapeutics is $11.68, 1,831.1% above the latest close of $0.60.
Is Actuate Therapeutics a buy, hold or sell?
Of 3 analysts covering Actuate Therapeutics, 3 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Actuate Therapeutics's EPS forecast?
Analysts forecast −$0.73 per share for 2026 (range −$0.85 to −$0.61); for 2027 the estimate is −$0.66.
When does Actuate Therapeutics report earnings?
Actuate Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.18.
Does Actuate Therapeutics usually beat earnings estimates?
Actuate Therapeutics reported EPS at or above the analyst estimate in 4 of the last 7 quarters.